GBI Research, the leading business intelligence provider, has released its latest research, “Clinical Trial Recruitment in Central Nervous System Disorders – Highest Number of Patients were Recruited for Clinical Trials in Schizophrenia”.
It gives a robust idea about the patient recruitment status by geography, by Sponsor Company, and by year for all the major CNS indications. Furthermore, the report provides profiles of prevalence with forecast data up to 2017 for all the major CNS indications. The major indications covered in the report are Alzheimer’s disease, Parkinson’s disease, Epilepsy, Schizophrenia and Depression. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
The Highest Number of Trials Were Conducted in Schizophrenia, in Terms of Trials Conducted for CNS from 2000-2009
The number of clinical trials for central nervous system diseases has increased for the past few years. The major indications which have been discussed in this report are selected on the basis of patient population and the pipeline molecules for that particular indication. On the basis of these two factors, the five major indications chosen were Alzheimer’s disease, Parkinson’s disease, Epilepsy, Schizophrenia and Depression. These five major indications have the highest number of pipeline molecules, and the patient population has a high unmet need for treatment.
GBI Research has analyzed all the clinical trials which started in the period 2000-2009, including completed, interventional and industry sponsored.
Clinical Trial Recruitment in CNS, Global, Total Number of Clinical Trials in Major Indications, 2000-2009
The highest number of clinical trials for central nervous system disorders was conducted for schizophrenia for the period 2000-2009. The highest proportion of trials in schizophrenia was conducted in Phase III. The number of clinical trials in Phase II was greater as compared to Phase III in Alzheimer’s disease trials, whereas for Parkinson’s disease Phase I trials were very few as compared to Phase II and III trials.
The Average Number of Patients Recruited per Trial was Highest for Alzheimer’s Disease from 2000-2009
The average number of patients recruited per trial depends on the protocol specifications and the phase of the trial. The number of patients required for a particular trial to justify an intervention is based on the phase of the trial. The highest number of patients was enrolled in Phase III, followed by Phase II and Phase I of clinical trials.
Clinical Trial Recruitment in CNS, Global, Average Number of Patients Recruited per Trial by Stage of Development, 2000-2009
GBI Research found that the number of patients recruited per trial is highest for Phase III trials of Alzheimer’s disease. The total number of patients recruited in Phase III Alzheimer’s trials was 601, which was the highest among all trials conducted in major CNS indications from 2000-2009.
CNS Attracted the Highest Number of Clinical Trials After Oncology for the Period 2005-2010
Pharmaceutical companies conduct clinical trials based on their therapeutic expertise. Not all pharmaceutical companies conduct trials in all the therapy areas. It is also based on the incidence of a disease in the particular geographic area. The number of clinical trials for a particular indication is higher in the countries which have high prevalence and incidence of those diseases.
CNS attracted 7,751 trials from 2005-2010, which was the highest among the non-oncology group, as compared to clinical trials for cardiovascular, infectious, respiratory and other diseases. The high number of trials indicated that CNS is a therapy area that is greatly focused on by the pharmaceutical companies. There are many pipeline molecules, along with large patient populations for indications such as Alzheimer’s disease, Parkinson’s disease, Epilepsy, Schizophrenia and Depression.
To order this report or find out more visit GBI Research.